Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANGUINATE for Delayed Graft Function in Kidney Transplant
NCT02490202Phase 3Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Sanguinate in delayed graft function (DGF), sponsored by Prolong Pharmaceuticals. Started Aug 2015; status: completed.
02
Drugs
Sanguinate
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02490202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490202.